Literature DB >> 7064832

The hyperventilation test as a method for developing successful therapy in Prinzmetal's angina.

L A Girotti, J R Crosatto, H Messuti, J C Kaski, E Dyszel, C A Rivas, L I Araujo, H D Vetulli, M B Rosenbaum.   

Abstract

In 10 cases of Prinzmetal's angina in which episodes of myocardial ischemia were easily and reproducibly induced by hyperventilation, this test was performed 111 times, 41 times under control conditions and 70 times during treatment with one or more of the following drugs: phentolamine, isosorbide dinitrate, propranolol, verapamil, nifedipine and amiodarone. Seventeen of 18 negative tests performed under the influence of a long-acting drug coincided with total remission of the patient's anginal episodes when this drug was administered on a short- or long-term basis. No patient died or sustained infarction during a follow-up period of 10.9 months. A negative test was thus a good indication that the clinical response to the corresponding drug would be favorable. The electrocardiographic changes and chest pain provoked by hyperventilation occurred not when alkalosis was greatest (hydrogen ion [pH] change from 7.42 to 7.58, p less than 0.001), but when pH was approaching normal or control values. The onset of electrocardiographic changes occurred an average of 175 seconds after the end of hyperventilation and, in two cases, the time lag was as much as 480 and 705 seconds, respectively. This raises several questions regarding the true mechanism triggering coronary spasm under such conditions. The hyperventilation test appears to be a useful and safe procedure for selecting the best possible drug for long-term treatment of Prinzmetal's angina as well as for comparing the relative efficacy of different drugs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7064832     DOI: 10.1016/0002-9149(82)91966-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Coronary artery spasm after intraperitoneal administration of cisplatin and etoposide during anesthesia.

Authors:  M Imai; Y Hanaoka; K Sugawara; O Kemmotsu
Journal:  J Anesth       Date:  1993-10       Impact factor: 2.078

Review 2.  Increased coronary tone in exertional angina: the beneficial effects of calcium antagonists.

Authors:  G Specchia; D Ardissino; S Ghio; P Barberis; M L Colombo; S De Servi
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Coronary artery spasm induced by respiratory alkalosis.

Authors:  Arifumi Kohyama; Masaaki Uno; Toshihiko Doi; Takao Saito
Journal:  J Anesth       Date:  1994-03       Impact factor: 2.078

4.  Chest pain and the hyperventilation syndrome--some aetiological considerations.

Authors:  L J Freeman; P G Nixon
Journal:  Postgrad Med J       Date:  1985-11       Impact factor: 2.401

5.  Hyperventilation and Raynaud's disease.

Authors:  H Williams; L J Freeman; P G Nixon
Journal:  Postgrad Med J       Date:  1987-05       Impact factor: 2.401

6.  Psychological and somatic symptoms of anxiety and risk of coronary heart disease: the health and social support prospective cohort study.

Authors:  Hermann Nabi; Martica Hall; Markku Koskenvuo; Archana Singh-Manoux; Tuula Oksanen; Sakari Suominen; Mika Kivimäki; Jussi Vahtera
Journal:  Biol Psychiatry       Date:  2009-10-12       Impact factor: 13.382

Review 7.  Calcium antagonists. Clinical use in the treatment of angina.

Authors:  P Théroux; Y Taeymans; D D Waters
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

8.  Are coronary artery spasm and progressive damage to the heart associated with the hyperventilation syndrome?

Authors:  L J Freeman; P G Nixon
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-28

Review 9.  A Practical Approach to Invasive Testing in Ischemia With No Obstructive Coronary Arteries (INOCA).

Authors:  Alexandra Bastiany; Christine Pacheco; Tara Sedlak; Jaqueline Saw; Steven E S Miner; Shuangbo Liu; Andrea Lavoie; Daniel H Kim; Martha Gulati; Michelle M Graham
Journal:  CJC Open       Date:  2022-05-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.